Edwards Lifesciences has secured European approval for its transcatheter tricuspid valve replacement system, which the company described as the first minimally invasive therapy of its kind to receive ...
SAN FRANCISCO, Oct. 26, 2023 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) announced one-year results from CLASP IID, the first randomized controlled trial that directly compares two ...
The Centers for Medicare & Medicaid Services have finalized a new National Coverage Determination for tricuspid transcatheter edge-to-edge repair (T-TEER) in patients suffering from symptomatic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results